Abstract

Objective To investigate the changes of serum miRNAlet-7a expression in clear renal cell carcinoma (cRCC) patients and the diagnostic value of let-7a for cRCC. Methods Forty patients with cRCC who were hospitalized in our hospital from November 2015 to February 2017, and Forty-two healthy subjects were enrolled in this study. Real-time quantitative polymerase chain reaction (qRT-PCR) was used to determine the levels of let-7a in serum samples. The association between serum let-7a levels and the clinical and pathological parameters of cRCC were analyzed, and the diagnostic efficacy of let-7a for cRCC was analyzed. Results ①The relative expression levels of let-7a in the experimental group and normal control group was(0.519±0.114)and(1.622±0.131), respectively. There was significant difference between the two groups (P 0.05). ③We used the receiver's characteristic curve (ROC) for analysis.The sensitivity was 81.4%, the specificity was 73.9%, the AUC was 0.794, and the 95% confidence interval was 0.657~0.912 for the optimal threshold of the relative expression of let-7a for cRCC. Conclusions The serum let-7a levels in patients with cRCC are down-regulated and the determination of let-7a has certain reference value for the diagnosis of cRCC and the judgment of the formation of tumor thrombus. PCR technology is mature, easy to operate, high amplification efficiency, has a certain clinical value. Key words: Kidney Neoplasms; Adenocarcinoma, Clear Cell; MicroRNAs

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.